Eli Lilly Launches Open Letter about Mounjaro® and Zepbound® Use
Lilly's Open Letter on Tirzepatide Medicines: Mounjaro and Zepbound should not be used for cosmetic weight loss. Patient safety is top priority.
Hypercholesterolemia News & Breaking Stories
UCLA Study Challenges Long-Held Beliefs Bioengineering Stem Cell Dynamics
UCLA scientists discover genetic instructions for boosting protein secretion, with big implications for biotech and cell therapy. #UCLA #StemCells #Biotech
U.S. FDA Approves New Version of Diabetes Drug Mounjaro for Weight Loss
New diabetes drug Zepbound, also known as tirzepatide, can be sold as a weight-loss drug, helping dieters lose 40-60 pounds.
Wegovy competitor Zepbound wins US approval for weight-loss jab amid gold rush
Miracle weight loss drugs are set to become more available after the US approves Zepbound, a cheaper competitor to Wegovy.
Get Weekly News Updates
Subscribe to SHUT Newsletter and be up to date with the current events. Be informed, don't settle for fake news.